CD274 and neoplasm: Although the advent of anti-PD-1/PD-L1 therapy has made it possible to achieve tumor eradication, disease remission and cure; clinically, however, the life-prolonging effectiveness of this approach is limited to a relatively small percentage (<20–30%) of patients, typically in individuals expressing high PD-L1 tumors.